VCKA SEC filings, in plain English
Everything Scilex Holding Co has filed with the SEC that we hold — 40 filings, newest first, 7 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: The 10-Q filed under Commission file number 001-39852 is that of Scilex Holding Company, the Delaware corporation formerly known as Vickers Vantage Corp. I, for the quarter ended June 30, 2026, with 8,493,000 shares of common stock outstanding as of August 10, 2026 and warrants exercisable at $397.89 per share. Why it matters: A biopharmaceutical de-SPAC naming a cryptocurrency treasury strategy and the 1940 Act investment-company test in the same risk list is a change in what the company holds, not only in what it sells. The condensed consolidated financial statements are not in the portion of the document read here, so no balance-sheet, revenue or cash figure is attributed.
What changed vs 2026-05-20deadline 2026-03-31 → 2026-09-30combination deadline, going-concern doubt1 moved · 1 with no prior record of ours
- Combination deadline
- 2026-03-312026-09-30
- Going-concern doubt
- stated · unchanged
SpacBrain reads this as 183 days later than the previous record.
The clause “1, 2026 and July 1, 2026 amortization payments due under the Tranche B Note to September 30, 2026. See Note 8 titled “Debt” to our unaudited condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form”…
The clause …“has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Item 1.01 8-K of Scilex Holding Company (Nasdaq: SCLX). On August 8, 2026 Scilex entered into a Promissory Note (Revolving Line of Credit) with Vivasor, Inc. as borrower, establishing in Vivasor's favour an uncommitted revolving line of credit of up to $20,000,000 with a stated maturity 120 months from the effective date. Drawdowns may be requested from time to time and repaid amounts reborrowed, but the facility is uncommitted and Scilex has no obligation to fund; any drawdown Scilex agrees to fund may be advanced in cash, in freely tradable Scilex securities, in shares of Datavault AI, Inc. Why it matters: Scilex is the lender, not the borrower: up to $20 million of its cash or securities may be advanced to a company its own CEO leads, over a ten-year term at 5%. Because the facility is uncommitted, no amount is required to be advanced and the filing states none has been.
What changed: 8-K of Scilex Holding Company. Item 1.01 and Item 2.01: on July 18, 2026 the Company entered a stock repurchase agreement under which it will sell back to Vivasor Holding Company 6,101,468 shares of Vivasor Series A-1 Preferred and 355,919 shares of Vivasor Series A-2 Preferred, acquired by the Company in January 2026, for an aggregate $11,999,762.28. The price is payable by wire, by assignment of Datavault AI, Inc. common stock held by Vivasor's subsidiary Vivasor, Inc., or a combination of the two. Why it matters: Payment is spread over almost a year in five tranches: $999,980.97 on July 18, 2026; $4,999,901.10 by September 30, 2026; and $1,999,960.07 in each of the windows ending December 31, 2026, March 31, 2027 and June 30, 2027. The report states that Dr. Henry Ji, the Company's Chief Executive Officer, President and Chairperson, is also Chief Executive Officer of Vivasor, and he signs the report; it names no independent approval of the related-party terms.
What changed: Scilex Holding Company, the Vickers Vantage Corp successor, entered a binding term sheet on July 3, 2026 with iHolding Group LLP of Almaty, Kazakhstan, contemplating that iHolding will purchase $100,000,000 of newly issued common stock at an expected $15.00 per share, about 6,666,667 shares. Completion is subject to due diligence, definitive agreements, board and stockholder approval and regulatory clearance, and the company warns there is no assurance the agreements will be signed or the investment consummated. Why it matters: A $100 million equity investment priced at a fixed $15.00 per share would be transformational for this company's balance sheet, and the fixed price means the investor takes the downside risk between signing and closing rather than repricing. The caution is the conditionality: completion turns on due diligence, definitive agreements, board and stockholder approval and regulatory clearance, and the company itself warns there is no assurance the agreements will be signed, so a former VCKA holder should treat this as an intention rather than committed capital.
What changed: Scilex Holding Company, successor to Vickers Vantage Corp. I, entered a binding term sheet on June 24, 2026 with Datavault AI Inc. to purchase 837 Bitcoin currently held by Datavault in a Biconomy digital wallet for $50 million. An initial payment of $30 million is contemplated, with the remaining $20 million payable in quarterly instalments beginning in the fourth quarter of 2026 and ending December 31, 2028. The purchase price may be paid in cash, in company common stock, in publicly traded securities of subsidiaries, or a combination, at the company's discretion. Why it matters: A pharmaceutical company is contracting to buy a fixed quantity of Bitcoin at a fixed dollar price payable over more than two years, which places the price risk on the buyer for the whole instalment period. The consideration may be settled in the company's own stock, so the eventual dilution is not determinable from this filing. A definitive agreement is still to be negotiated.
What changed: Item 5.07: Scilex Holding Company held its 2026 annual meeting on June 24, 2026. Represented virtually or by proxy were 29,057,097 shares of Series A preferred stock, 100% of that class outstanding, and 5,389,081 shares of common stock, approximately 63.5% of the 8,491,267 common shares outstanding, both measured as of the April 28, 2026 record date. The Series A holder voted together with common holders and not as a separate class, on an as-converted basis, for an aggregate of 848,106 votes. Why it matters: The capital structure is the story: a single Series A preferred holder representing 29,057,097 shares votes on an as-converted basis for 848,106 votes against 8,491,267 common shares outstanding, so the preferred carries roughly 9% of the combined vote while sitting ahead of common in any distribution. Common holders retain voting control at this meeting, but the small common share count points to a reverse split and the preferred overhang is the structural feature to track.
- What changed vs 2025-11-14deadline 2025-12-31 → 2026-03-31
combination deadline, going-concern doubt, mandate language1 moved · 2 with no prior record of ours
- Combination deadline
- 2025-12-312026-03-31
- Going-concern doubt
- stated · unchanged
- Mandate language
- We intend to pursue an income generating strategy whereby we…not matched in this filing
SpacBrain reads this as 90 days later than the previous record.
The clause …“Payment Amount”) in full, extending the maturity date of the Oramed Note to March 31, 2026 and waiving any make-whole payment otherwise due thereunder upon prepayment. On March 29, 2026, the Company received notice from Oramed”…
The clause …“has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Scilex Holding Company (successor to SPAC Vickers Vantage Corp, ticker VCKA) called its 2026 annual meeting for Wednesday, June 24, 2026 at 9:00 a.m. Pacific Time, held virtually, record date April 28, 2026, with the record date share count given as 8,491,267. A quorum requires holders of a majority of the voting power of the outstanding common stock and Series A Preferred Stock voting together. Each current non-employee director held options on 20,000 shares at December 31, 2025: Dr. Chun, Mr. Followwill and Dr. Wu. Dr. Navani resigned from the board effective September 22, 2025. Why it matters: Routine annual governance with no trust or redemption mechanics left from the Vickers SPAC. The capital structure is the item to watch: Series A Preferred votes together with common for quorum and voting purposes, so a preferred class senior in liquidation also carries influence over board outcomes, and the very small common share count implies prior reverse-split compression. Director option holdings of 20,000 shares each are immaterial against that base, so the dilution risk sits with the preferred and any future issuance rather than with board pay.
combination deadlinenothing moved · 1 with no prior record of ours
- Combination deadline
- not previously extracted2025-12-31
The clause “Maturity Date under and as set forth in the Oramed Note from March 21, 2025 to December 31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of 92,857 shares of Common Stock held by SCLX JV. The”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
- What changed vs 2025-03-31deadline 2025-12-31 → 2026-04-30
combination deadline, going-concern doubt, mandate language1 moved · 2 with no prior record of ours
- Combination deadline
- 2025-12-312026-04-30
- Going-concern doubt
- stated · unchanged
- Mandate language
- we intend to pursue therapeutics that address markets served… · unchanged
SpacBrain reads this as 120 days later than the previous record.
The clause …“an agreement to extend the Letter commitment period from December 31, 2025 to April 30, 2026. As such, the Company now has until April 30, 2026, to fund the remaining Commitment Amount of $ 1,500,000 . F-”…
The clause …“operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. Risks Related to our Commercial Operations and Product Development • We obtain, or”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.